Parker Institute for Cancer Immunotherapy, JDRF and the Helmsley Charitable Trust Form Cancer and Diabetes Research Initiative
May 29, 2019
May 29, 2019
NEW YORK, May 29 -- JDRF, a charitable 501(c)(3) organization dedicated to funding type 1 diabetes research, issued the following news release:
* * *
- Collaborative funds $10 million in research to understand, predict and prevent insulin-dependent diabetes following checkpoint therapy for cancer
* * *
Immunotherapy has become a first-line treatment for several types of cancer. Over time, researchers have observed that some patients develop aut . . .
* * *
- Collaborative funds $10 million in research to understand, predict and prevent insulin-dependent diabetes following checkpoint therapy for cancer
* * *
Immunotherapy has become a first-line treatment for several types of cancer. Over time, researchers have observed that some patients develop aut . . .